Chantix Settlement to Pay $44M to Past Users for Cancer Risks

Final Chantix class action settlement approval hearing is slated to be held on October 13, 2026.

Pfizer has agreed to pay $44 million to resolve a class action lawsuit alleging Chantix was contaminated with chemicals that may have increased users’ risk of developing cancer.

Details of the proposed $44 million settlement were released last month, outlining compensation for individuals and third-party payers who purchased Chantix between September 2015 and September 2021.

Chantix (varenicline) was approved by the FDA in 2006 as a prescription smoking-cessation drug. However, in the years that followed, the medication drew safety concerns over reports of serious neuropsychiatric side effects, including vivid nightmares, suicidal thoughts and violent behavior.

Chantix Nitrosamine Risks

Concerns about nitrosamine contamination in prescription drugs first emerged in 2018, when a series of valsartan recalls were announced after the hypertension medication was found to contain unsafe levels of N-nitrosodimethylamine (NDMA), a known carcinogen. Similar contamination problems were later identified in several other medications, including Zantac, metformin and Chantix.

In 2021, testing revealed that certain Chantix tablets contained elevated levels of N-nitroso-varenicline, a nitrosamine that may increase the risk of cancer with prolonged exposure. The contamination was believed to be associated with the drug manufacturing process.

Pfizer first announced the problem in June 2021, when it recalled a single Chantix lot distributed in Canada. The company recalled 12 additional U.S. batches in July, four more lots in August, and ultimately expanded the Chantix recall to include all lots distributed in the United States in September 2021.

The contamination problems subsequently led to multiple Chantix class action lawsuits against Pfizer, alleging the company knew or should have known its manufacturing process could expose consumers to unsafe levels of nitrosamines and an increased risk of cancer.

Chantix Lawsuit Consolidation

All Chantix class action lawsuits were consolidated in late 2022 in the Southern District of New York before U.S. District Judge Katherine Polk Failla, allowing the cases to move through coordinated discovery and other pretrial proceedings.

The lawsuits alleged Pfizer failed to follow current good manufacturing practices, resulting in Chantix being sold with undisclosed nitrosamine contamination. Pfizer denies wrongdoing and maintains that it did not violate the law, but agreed to the settlement to avoid the cost and uncertainty of continued litigation.

The proposed settlement received preliminary approval this summer and establishes a $44 million fund for individuals and third-party payers who purchased Chantix in the United States or its territories between September 29, 2015, and September 17, 2021. The fund will also be used to pay settlement administration costs, attorneys’ fees, litigation expenses and awards to class representatives.

Eligible class members were required to submit a claim by September 14, 2026. Those who remained in the class but did not file a claim will receive no payment and will give up their right to separately pursue Pfizer over the same allegations.

Consumer payments will be distributed on a pro rata basis according to the amount each claimant paid for Chantix and cannot exceed the amount they actually spent. Consumer claims as a group are capped at 20% of the available settlement fund, with the remaining money distributed among qualifying third-party payers based on their documented payments.

A final approval hearing is scheduled for October 13, 2026, when Judge Failla will consider whether the settlement is fair and should receive final approval.

Sign up for more legal news that could affect you or your family.